Skip to main contentAI and Advanced
/
NEULANDLAB · NSEBSE SENSEX74,336.45+0.45%BSE |
NIFTY 5023,217.6+0.43%NSE |
NIFTY BANK56,292.45+0.89%NSE |
NIFTY IT29,087.65-1.58%NSE |
NIFTY AUTO26,893.65+0.51%NSE |
NIFTY FMCG45,559+1.63%NSE |
NIFTY PHARMA26,146.2-0.16%NSE |
NIFTY 50022,532+0.24%NSE |
NE
NSE · Equity shares · Major Drugs30.00 · 0.13%
Neuland Laboratories NEULANDLAB
NSE:INR 22,625
BSE:INR 22,702.65
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for NEULANDLAB
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 22,595
Day rangeINR 21,855 — INR 23,125
52-week rangeINR 11,500 — INR 24,225
Volume50,779
Market cap27,583.36
P/E42.39
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)2,022.99
Net Income (INR Cr)364
Rev Growth (5 Year %)16.64
EPS Growth (5 Year %)35.18
P/E Ratio42.39
Book Value1,238.32
EPS286.77
Price/BV18.27Computed
Research path: Interpret Neuland Laboratories's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
NEULANDLABNeuland Laboratories1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 2,930.14 | 2,179.88 | 1,832.56 |
| Accumulated Depreciation Total | -333.56 | -268.9 | -256.77 |
| Cash Equivalents | 0 | 63.05 | 77.06 |
| Other Liabilities Total | 15.86 | 7.22 | 7.61 |
| Accrued Expenses | 97.76 | 78.53 | 101.06 |
| Long Term Debt | 154.85 | 85.45 | 34.32 |
| Common Stock Total | 12.9 | 12.9 | 12.9 |
| Other Equity Total | -2.65 | -9.27 | -3.12 |
| Other Current Assets Total | 28.29 | 14.32 | 0.25 |
| Prepaid Expenses | 13.98 | 11.72 | 11.14 |
| Total Assets | 2,930.14 | 2,179.88 | 1,832.56 |
| Current Portof LT Debt/Capital Leases | 40.63 | 47.79 | 41.27 |
| Additional Paid-In Capital | 497.77 | 497.77 | 497.77 |
| Cash | 76.67 | 68.88 | 10.52 |
| Total Equity | 1,874.47 | 1,524.81 | 1,282.7 |
| Long Term Investments | 1.98 | 1.53 | 20.31 |
| Retained Earnings(Accumulated Deficit) | 1,371.16 | 1,022.56 | 780.41 |
| Total Common Shares Outstanding | 1.28 | 1.28 | 1.28 |
| Property/Plant/Equipment Total-Gross | 1,435.35 | 987.17 | 825.38 |
| Tangible Book Valueper Share Common Eq | 1,238.32 | 966.88 | 780.04 |
| Goodwill Net | 279.46 | 279.46 | 279.46 |
| Total Liabilities | 1,055.66 | 655.08 | 549.86 |
| Total Debt | 301.27 | 157.14 | 95.39 |
| Short Term Investments | 250 | 220.25 | 29.08 |
| Cashand Short Term Investments | 326.67 | 352.18 | 116.66 |
| Total Receivables Net | 592.45 | 353.36 | 426.87 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 |
| Deferred Income Tax | 68.96 | 72.82 | 60.44 |
| Accounts Receivable-Trade Net | 545.69 | 317.94 | 376.41 |
| Property/Plant/Equipment Total-Net | 1,101.79 | 718.27 | 568.61 |
| Total Current Liabilities | 710.2 | 465.69 | 427.68 |
| Total Inventory | 521.74 | 407.92 | 366.16 |
| Accounts Payable | 269.14 | 252.2 | 191.96 |
| Other Currentliabilities Total | 302.66 | 87.16 | 93.4 |
| Total Long Term Debt | 260.64 | 109.35 | 54.12 |
| Intangibles Net | 6.27 | 4.85 | 2.46 |
| Other Long Term Assets Total | 12.11 | 9.59 | 8.64 |
| Note Receivable-Long Term | 45.41 | 26.69 | 32 |
| Unrealized Gain(Loss) | -4.71 | 0.84 | -5.26 |
| Total Current Assets | 1,483.13 | 1,139.5 | 921.08 |
| Capital Lease Obligations | 105.79 | 23.89 | 19.8 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio2.3
Price to Sale Ratio13.63
Growth
Debt 5Yr CAGR %10.57
Margins
Operating Margin 12m23.86
Operating Margin 5y Avg20.63
Net Profit Margin 12m17.99
Net Profit Margin 5y15.99
Yield
Dividend Yield %0.17
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk39.13
Analyst consensus
ConsensusStrong Buy
Consensus score1.50
Analyst opinions4
Strong Sell count0
Sell count0
Hold count0
Buy count2
Strong Buy count2
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Aurobindo Pharma | INR 1,589.5 | 91,456.32 | 25.09 | — |
| Pfizer | INR 4,900 | 22,334.85 | 27.53 | — |
| Unichem Laboratories | INR 493.05 | 3,476.61 | 54.27 | — |
| Jagsonpal Pharmaceuticals | INR 236.75 | 1,560.88 | 34.27 | — |
| Themis Medicare | INR 112.65 | 1,035.27 | 632.19 | — |
Shareholding
Ownership
- Promoter
- 32.62%
- FII
- 21.08%
- MF
- 12.66%
- Other
- 33.64%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Neuland Laboratories Ltd Upgraded to Sell on Technical Improvements Despite Financial Challenges - MarketsMojoMarket news · 17 Jul 2026, 1:51 am
Neuland Laboratories Ltd Upgraded to Sell on Technical Improvements Despite Financial Challenges MarketsMojo
Neuland Laboratories Ltd is Rated Buy - MarketsMojoMarket news · 16 Jul 2026, 10:57 am
Neuland Laboratories Ltd is Rated Buy MarketsMojo
Neuland Laboratories to declare ₹34 dividend at AGM on Aug 4 - scanx.tradeMarket news · 9 Jul 2026, 9:25 pm
Neuland Laboratories to declare ₹34 dividend at AGM on Aug 4 scanx.trade
Neuland Laboratories announces 42nd AGM to be held virtually on August 4, 2026 - Business UpturnMarket news · 9 Jul 2026, 8:32 pm
Neuland Laboratories announces 42nd AGM to be held virtually on August 4, 2026 Business Upturn
Broad-Based Technical Strength Lifts Neuland Laboratories Ltd to 52-Week High of Rs 19800 - MarketsMojoMarket news · 9 Jul 2026, 1:09 pm
Broad-Based Technical Strength Lifts Neuland Laboratories Ltd to 52-Week High of Rs 19800 MarketsMojo
Neuland Laboratories Ltd Hits All-Time High of Rs 19,745 as Momentum Builds Across Timeframes - MarketsMojoMarket news · 9 Jul 2026, 12:53 pm
Neuland Laboratories Ltd Hits All-Time High of Rs 19,745 as Momentum Builds Across Timeframes MarketsMojo
Corporate actions
Events
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.34.0000 per share(340%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingPOM
- board MeetingsQuarterly Results
Rusaka Markets Community
Discussion and sentiment for Neuland Laboratories
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Neuland Laboratories Ltd. is a global provider of active pharmaceutical ingredients (APIs) contract development and manufacturing organization (CDMO) services. It is focused on manufacture and sale of active pharmaceutical ingredients and allied services. It supports biotechnology and pharmaceutical companies in the design, development and manufacturing of complex APIs. It has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). It develops and manufactures non-exclusive APIs both Prime APIs comprising large volume, mature molecules, and specialty APIs comprising lower volume, complex molecules with less competition. It develops small molecules and peptides for clinical trials and beyond. It provides an end-to-end continuum of customized services from early-stage drug development (Pre-IND) through to commercial manufacturing of complex APIs, including process development, process optimization, analytical testing, and regulatory support.
Company facts
- Industry
- Major Drugs
- Sector
- Major Drugs
- NSE Code
- NEULANDLAB
- BSE Code
- 524558
Questions
Stock FAQ
What is the symbol and ISIN of Neuland Laboratories?
Neuland Laboratories has the symbol NEULANDLAB and ISIN - INE794A01010.
What is the current price of Neuland Laboratories?
Neuland Laboratories is currently trading at INR 22,625.00.
What are the year high and year low of Neuland Laboratories?
Neuland Laboratories has a year high of INR 24,225.00 and a year low of INR 11,500.00.
What is the market capitalization of Neuland Laboratories?
Neuland Laboratories has a market capitalization of INR 27,583.36 crore.
What is the P/E ratio of Neuland Laboratories?
Neuland Laboratories has a P/E ratio of 42.39.
What is the dividend yield of Neuland Laboratories?
Neuland Laboratories has a dividend yield of 0.17%.
How is the financial performance of Neuland Laboratories based on revenue, net income, and EPS?
Neuland Laboratories has revenue of INR 2,022.99 crore, net income of INR 364.00 crore, and EPS of INR 283.69.
What is the book value of Neuland Laboratories?
Neuland Laboratories has a book value of INR 1,238.32.
What is the debt-to-equity ratio of Neuland Laboratories?
Neuland Laboratories has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Neuland Laboratories?
Neuland Laboratories has a price-to-book ratio of 18.27 and a price-to-sales ratio of 13.63.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.